Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

qpharma pty ltd - n-octyl bicycloheptene dicarboximide; piperonyl butoxide; pyrethrins - topical solution/suspension - n-octyl bicycloheptene dicarboximide bicyclo active 30.0 g/l; piperonyl butoxide benzodioxole active 18.0 g/l; pyrethrins pyrethroid-pyrethrin active 10.0 g/l - parasiticides

Canada - English - Health Canada

biogen canada inc - interferon beta-1a; water - powder for solution - 30mcg; 1.1ml - interferon beta-1a 30mcg; water 1.1ml - immunomodulatory agents

Canada - English - Health Canada

biogen canada inc - interferon beta-1a - powder for solution - 60mcg - interferon beta-1a 60mcg - immunomodulatory agents

Canada - English - Health Canada

biogen canada inc - interferon beta-1a - solution - 30mcg - interferon beta-1a 30mcg - immunomodulatory agents

Canada - English - Health Canada

laboratoire m2 inc - thymol - solution - 23% - thymol 23% - cattle

Canada - English - Health Canada

horizon therapeutics ireland dac - cysteamine (cysteamine bitartrate) - capsule (delayed release) - 25mg - cysteamine (cysteamine bitartrate) 25mg - other miscellaneous therapeutic agents

Canada - English - Health Canada

horizon therapeutics ireland dac - cysteamine (cysteamine bitartrate) - capsule (delayed release) - 75mg - cysteamine (cysteamine bitartrate) 75mg - other miscellaneous therapeutic agents

Australia - English - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - pertuzumab, quantity: 420 mg - injection, intravenous infusion - excipient ingredients: histidine; sucrose; glacial acetic acid; water for injections; polysorbate 20 - early breast cancer perjeta is indicated in combination with trastuzumab and chemotherapy for:,- the neoadjuvant treatment of patients with her2-positive inflammatory or locally advanced, or early stage (either > 2 cm in diameter or node positive) breast cancer as part of a complete treatment regimen for early breast cancer,-the adjuvant treatment of patients with her2-positive early breast cancer at high risk of recurrence.,metastatic breast cancer,perjeta is indicated in combination with trastuzumab and docetaxel for patients with metastatic her2-positive breast cancer who have not received prior anti-her2 therapy or chemotherapy for their metastatic disease.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

roche products ltd - pertuzumab - solution for infusion - 30mg/1ml

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

roche diagnostics gmbh - pertuzumab - concentrate for solution for infusion - 30mg/ml